Description

[2R,6R,11R,(-)]-1,2,3,4,5,6-Hexahydro-6,11-Dimethyl-3-(3-Furanylmethyl)-2,6-Methano-3-Benzazocin-8-Ol is a high-purity, stereochemically defined benzazocine derivative with significant pharmacological interest. This compound serves as a critical advanced pharmaceutical intermediate and a valuable reference standard for research and development. It is primarily required by pharmaceutical R&D laboratories and fine chemical manufacturers engaged in the synthesis of novel therapeutic agents.

Application

• Pharmaceutical Intermediate: Key building block in the synthesis of complex active pharmaceutical ingredients (APIs) targeting the central nervous system.
• Reference Standard: Used in analytical method development, validation, and quality control for ensuring batch-to-batch consistency in API production.
• Medicinal Chemistry Research: A crucial compound for structure-activity relationship (SAR) studies and the development of new pharmacophores.
• Preclinical Studies: Serves as a standard material in pharmacological and toxicological evaluations during drug discovery phases.
• Process Chemistry Development: Used to optimize synthetic routes and scale-up processes for related benzazocine compounds.
• Academic Research: A valuable tool for universities and research institutes studying opioid receptor pharmacology and related medicinal chemistry.

Basic Information

Item	Detail
Product Name	[2R,6R,11R,(-)]-1,2,3,4,5,6-Hexahydro-6,11-Dimethyl-3-(3-Furanylmethyl)-2,6-Methano-3-Benzazocin-8-Ol
CAS No.	56649-73-1
Molecular Formula	C21H27NO2
Molecular Weight	325.45 g/mol
Synonyms	(-)-Pentazocine; (2R,6R,11R)-(-)-Pentazocine; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-furanylmethyl)-2,6-methano-3-benzazocin-8-ol; Talwin (stereoisomer); Fortral (stereoisomer); Win 20228; Benzazocine derivative; (-)-1,2,3,4,5,6-Hexahydro-cis-6,11-dimethyl-3-(3-methyl-2-furylmethyl)-2,6-methano-3-benzazocin-8-ol
EINECS	Contact for details

Quality Control

Our [2R,6R,11R,(-)]-Pentazocine is manufactured under strict quality systems to ensure high purity and batch-to-batch consistency. Each lot undergoes comprehensive analytical testing, including HPLC for assay and chiral purity, and is accompanied by a detailed Certificate of Analysis (COA). We support compliance with cGMP standards for pharmaceutical intermediates, and specifications can be aligned with client-specific pharmacopeial requirements.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at controlled room temperature (15-25°C). The compound is light-sensitive and should be handled under appropriate conditions to maintain stability.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥98.0%
Chiral Purity (HPLC)	≥99.0% ee
Related Substances (HPLC)	Total impurities ≤2.0%
Residual Solvents (GC)	Complies with ICH Q3C
Loss on Drying	≤0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.